PM
OKUR

Prosight Management’s OnKure Therapeutics OKUR Stock Holding History

Prosight Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46M Sell
978,992
-1,175,389
-55% -$5.04M 0.77% 24
2026
Q1 		$8.92M Buy
2,154,381
+1,337,472
+164% +$4.13M 1.46% 21
2025
Q4 		$2.37M Buy
816,909
+548,950
+205% +$1.64M 0.49% 31
2025
Q3 		$737K Buy
267,959
+108,267
+68% +$268K 0.17% 36
2025
Q2 		$382K Sell
159,692
-26,878
-14% -$70.5K 0.09% 37
2025
Q1 		$802K Buy
186,570
+122,816
+193% +$691K 0.26% 34
2024
Q4 		$548K Buy
+63,754
New +$965K 0.15% 36
2021
Q3 		– Sell
-5,493
Closed -$513K – 54
2021
Q2 		$513K Buy
+5,493
New +$613K 0.32% 42

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prosight Management's OKUR Position: Q2 2026 in Review

Prosight Management reduced its OnKure Therapeutics (OKUR) stake by 55% in Q2 2026, selling an estimated $5.04M and leaving 978,992 shares worth $4.46M. The position accounts for 0.77% of the portfolio, ranked #24.

Prosight Management first reported a position in OKUR in Q2 2021 and has held it in 8 quarters since. The position peaked at $8.92M in Q1 2026. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Prosight Management held 978,992 shares of OnKure Therapeutics worth $4.46M as of Q2 2026.
  • Prosight Management sold 1,175,389 OnKure Therapeutics shares in Q2 2026, an estimated $5.04M.
  • OnKure Therapeutics made up 0.77% of Prosight Management's portfolio in Q2 2026, its #24 holding.
  • Prosight Management first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • Prosight Management's OnKure Therapeutics position peaked at $8.92M in Q1 2026.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.